Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CRMD · Nasdaq · United States · Pharmaceutical Preparations
In shortCorMedix Inc. is profitable, generates cash and holds more cash than debt, with revenue growing (+617.0% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 48.2% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 52.3% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 66.6% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 29.3% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.11× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 53.97× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.07 | 50/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 55.4% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.06× | 95/100 |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 3 | 0/100 |
| Revenue growth volatility | 381.7% | 0/100 |
| Operating margin volatility | 22070.6% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 1582.8% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 0.2 | 0.1 | – | 43 | 312 |
| Cost of revenue | 0.1 | 0 | – | 3 | 22 |
| Gross profit | 0 | 0.1 | – | 40 | 276 |
| Research & development | 13 | 11 | 13 | 3.9 | 19 |
| Selling, general & admin | 16 | 20 | 36 | – | – |
| Operating income | (29) | (31) | (49) | (22) | 150 |
| Interest expense | 0 | 0 | 0 | 0 | 2.8 |
| Pre-tax income | (29) | (30) | (46) | (19) | 150 |
| Income tax | (1.3) | (0.6) | – | (1.4) | (13) |
| Net income | (28) | (30) | (46) | (18) | 163 |
| Diluted EPS | −$0.75 | −$0.74 | −$0.91 | −$0.30 | $2.04 |
| Diluted shares (millions) | 38 | 40 | 51 | 0.1 | 0.1 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
3.07 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 13, 2026